Now or Later? The Role of Neoadjuvant Treatment in Advanced Endometrial Cancer: A Systematic Review

Overview

Journal Healthcare (Basel)

Specialty Health Services

Date 2024 Dec 17

PMID 39685026

Authors

Carlo Ronsini

Irene Iavarone

Alessandro Carotenuto

Antonio Raffone

Giada Andreoli

Stefania Napolitano

Pasquale De Franciscis

Domenico Ambrosio

Luigi Cobellis

Affiliations

Soon will be listed here.

Abstract

Endometrial cancer (EC) is, nowadays, the most frequent gynecological malignancy worldwide. The main treatment approach for EC is surgery, especially for early-stage tumors. For advanced EC, chemotherapy (CT) with carboplatin and paclitaxel is the standard treatment, especially for women with metastatic or recurrent disease. The present systematic review aimed to establish whether neoadjuvant treatment regimens with CT and/or radiotherapy (RT) lead to better survival outcomes compared to upfront surgery in advanced EC. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, through the string "(("Endometrial Neoplasms"[Mesh]) AND "Hysterectomy"[Mesh]) AND "Radiotherapy"[Mesh] AND Chemotherapy", the selection of articles was made. A quality assessment was conducted using the Newcastle-Ottawa Scale (NOS). The studies included patients with EC with survival and recurrence outcomes-patients treated with upfront surgery or neoadjuvant CT ± External Beam Radiation Therapy (EBRT) or CT ± Brachytherapy (BT). According to the selected evidence in the scientific literature, the 5-year DFS was 21.3% for upfront surgery and ranged from 42 to 73% for neoadjuvant chemotherapy. Also, the 5-year OS was 6.2 to 49.7% with upfront surgery and 15.5 to 100% for neoadjuvant schemes. None of the studies dedicated to surgery reported the 5-year Recurrence Rate (RR), while in the neoadjuvant treatments, it ranged from 27 to 64.7%. The literature's paucity of data makes it difficult to compare neoadjuvant therapy regimens with upfront surgery in advanced endometrial carcinoma. Nevertheless, the current data show more encouraging results for the neoadjuvant treatment group.

References

Vargo J, Beriwal S . Image-based brachytherapy for cervical cancer. World J Clin Oncol. 2014; 5(5):921-30. PMC: 4259954. DOI: 10.5306/wjco.v5.i5.921. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

Sakai K, Yamagami W, Machida H, Ebina Y, Kobayashi Y, Tabata T . A retrospective study for investigating the outcomes of endometrial cancer treated with radiotherapy. Int J Gynaecol Obstet. 2021; 156(2):262-269. DOI: 10.1002/ijgo.13725. View

Randall M, Filiaci V, Muss H, Spirtos N, Mannel R, Fowler J . Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2005; 24(1):36-44. DOI: 10.1200/JCO.2004.00.7617. View

Conway J, Lukovic J, Ferguson S, Zhang J, Xu W, Dhani N . Clinical Outcomes of Surgically Unresectable Endometrial Cancers. Am J Clin Oncol. 2019; 42(10):777-782. DOI: 10.1097/COC.0000000000000600. View

. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int J Gynecol Cancer. 2023; 33(1):109-117. DOI: 10.1136/ijgc-2022-004039. View

Yano M, Aso S, Sato M, Aoyagi Y, Matsumoto H, Nasu K . Pembrolizumab and Radiotherapy for Platinum-refractory Recurrent Uterine Carcinosarcoma With an Abscopal Effect: A Case Report. Anticancer Res. 2020; 40(7):4131-4135. DOI: 10.21873/anticanres.14412. View

Zhu J, Wen H, Bi R, Wu X . Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study. J Gynecol Oncol. 2015; 27(2):e18. PMC: 4717223. DOI: 10.3802/jgo.2016.27.e18. View

Chinnadurai A, Breadner D, Baloush Z, Lohmann A, Black M, DSouza D . Adjuvant carboplatin and paclitaxel with "sandwich" method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single-institution. J Gynecol Oncol. 2023; 35(2):e16. PMC: 10948991. DOI: 10.3802/jgo.2024.35.e16. View

10.

Ronsini C, Iavarone I, Reino A, Vastarella M, De Franciscis P, Sangiovanni A . Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review. J Pers Med. 2023; 13(6). PMC: 10304022. DOI: 10.3390/jpm13060886. View

11.

Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza M, Marnitz S . ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021; 31(1):12-39. DOI: 10.1136/ijgc-2020-002230. View

12.

Haie-Meder C, Mazeron R, Magne N . Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers. Radiother Oncol. 2010; 96(3):351-5. DOI: 10.1016/j.radonc.2010.07.010. View

13.

Iheagwara U, Vargo J, Chen K, Burton D, Taylor S, Berger J . Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix. Pract Radiat Oncol. 2019; 9(4):248-256. DOI: 10.1016/j.prro.2019.02.007. View

14.

Vargo J, Boisen M, Comerci J, Kim H, Houser C, Sukumvanich P . Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria. Gynecol Oncol. 2014; 135(2):190-5. DOI: 10.1016/j.ygyno.2014.09.001. View

15.

Boothe D, Orton A, Kim J, Poppe M, Werner T, Gaffney D . Does Early Chemotherapy Improve Survival in Advanced Endometrial Cancer?. Am J Clin Oncol. 2019; 42(11):813-817. DOI: 10.1097/COC.0000000000000616. View

16.

Wilkinson-Ryan I, Binder P, Pourabolghasem S, Al-Hammadi N, Fuh K, Hagemann A . Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial cancer. Gynecol Oncol. 2014; 134(1):24-8. DOI: 10.1016/j.ygyno.2014.05.002. View

17.

Petrillo M, Zucchetti M, Cianci S, Morosi L, Ronsini C, Colombo A . Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study. J Gynecol Oncol. 2019; 30(4):e59. PMC: 6543101. DOI: 10.3802/jgo.2019.30.e59. View

18.

Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J . ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2015; 26(1):2-30. PMC: 4679344. DOI: 10.1097/IGC.0000000000000609. View

19.

Oaknin A, Bosse T, Creutzberg C, Giornelli G, Harter P, Joly F . Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(9):860-877. DOI: 10.1016/j.annonc.2022.05.009. View

20.

Perera J, Hoskin P . Adjuvant Therapy for High-risk Endometrial Carcinoma. Clin Oncol (R Coll Radiol). 2021; 33(9):560-566. DOI: 10.1016/j.clon.2021.05.009. View